“Be a legend” is the tagline for a new line of men’s sexual wellness products marketed under the brand name Idavøll.
UK’s Idavøll Viking-Themed Supplement Seeks To Conquer Men’s Sexual Wellness Category
UK start-up Idavøll has created a “sexual performance” supplement containing a mixture of botanicals, minerals and amino acids designed to contribute towards optimal stamina, blood flow, testosterone levels and mental performance. Speaking exclusively to HBW Insight, the firm's CEO Dan Barron reveals plans to take the Viking themed brand to Europe, China and the US.
More from United Kingdom
• By
Maxwellia's “bold, honest, and completely unfiltered” campaign for Evana menstrual health brand tells the story of a woman dealing with the realities of a heavy period, showing “real blood, real leaks.”
• By
HBW Insight catches up with Maxwellia CEO Anna Maxwell to discuss her company's journey so far, and what she sees as the opportunities for Rx-to-OTC switch in UK women's health and beyond.
• By
Pirilieve Hayfever Relief Tablets contain 120mg fexofenadine hydrochloride, which the firm notes is an active ingredient that was “previously only available behind pharmacy counters.”
• By
Advercheck managing director James Walmsley talks to HBW Insight about the challenges facing consumer health companies today as they move away from the prescription medicines sector and its pipeline of switchable ingredients towards self-care and prevention.
More from Europe
• By
Like many European firms, Stada Arzneimittel's 2024 earnings were held back by a soft cough, cold and flu season. However, key launches in its home market Germany and in the Middle East offset this impact and led to 3% organic growth for Stada's Consumer Healthcare business.
• By
Maxwellia's “bold, honest, and completely unfiltered” campaign for Evana menstrual health brand tells the story of a woman dealing with the realities of a heavy period, showing “real blood, real leaks.”
• By
HBW Insight catches up with Maxwellia CEO Anna Maxwell to discuss her company's journey so far, and what she sees as the opportunities for Rx-to-OTC switch in UK women's health and beyond.